ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Inclusion Criteria:

- Active subfoveal NVAMD

Exclusion Criteria:

- History or evidence of severe cardiac disease

- Any major surgical procedure within one month of trial entry

- Subjects with a clinically significant laboratory value

- Any treatment with an investigational agent in the past 60 days for any condition

- Women who are pregnant or nursing

- Known serious allergies to the fluorescein dye used in angiography, povidone iodine,
to the components of the ranibizumab formulation, or to the components of the Zimura
formulation

- Any prior treatment for AMD other than oral supplements of vitamins and minerals